Cargando…
Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis
PURPOSE: To compare the efficacy and safety of transarterial chemoembolization (TACE) plus sorafenib and immune checkpoint inhibitors (T+S+ICIs) and TACE plus sorafenib (T+S) when treating patients with advanced hepatocellular carcinoma (HCC) who have previously received locoregional treatment. MATE...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513034/ https://www.ncbi.nlm.nih.gov/pubmed/36176392 http://dx.doi.org/10.3389/fonc.2022.914385 |
_version_ | 1784797964889227264 |
---|---|
author | Yang, Xue-Gang Sun, Yan-Yuan Wang, Hai-Qing Li, De-Shan Xu, Guo-Hui Huang, Xiao-Qi |
author_facet | Yang, Xue-Gang Sun, Yan-Yuan Wang, Hai-Qing Li, De-Shan Xu, Guo-Hui Huang, Xiao-Qi |
author_sort | Yang, Xue-Gang |
collection | PubMed |
description | PURPOSE: To compare the efficacy and safety of transarterial chemoembolization (TACE) plus sorafenib and immune checkpoint inhibitors (T+S+ICIs) and TACE plus sorafenib (T+S) when treating patients with advanced hepatocellular carcinoma (HCC) who have previously received locoregional treatment. MATERIALS AND METHODS: A retrospective analysis was performed on the patients with Barcelona Clinic Liver Cancer (BCLC) stage C HCC from May 2019 to December 2020. These patients were treated with locoregional therapy and showed radiographic progression after the treatment. Patients received either T+S+ICIs or T+S. The outcomes, including disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety, were compared. The propensity score matching (PSM) methodology was used to reduce the influence of confounding factors on the outcomes. RESULTS: Forty-three patients were included in the T+S group and 33 in the T+S+ICI group. After PSM (n = 29 in each group), patients who received T+S+ICIs had a higher DCR (82.8% vs. 58.6%, p = 0.043), longer median PFS (6.9 vs. 3.8 months, p = 0.003), and longer median OS (12.3 vs. 6.3 months, p = 0.008) than those who underwent T+S. Eastern Cooperative Oncology Group performance status was an independent predictor of PFS, and age was an independent predictor of OS. The incidence of treatment-related adverse events in T+S+ICIs was well controlled. CONCLUSIONS: Compared with TACE combined with sorafenib, TACE combined with sorafenib plus ICIs is a potentially safe and effective treatment regimen for patients with advanced HCC who previously received locoregional treatment. |
format | Online Article Text |
id | pubmed-9513034 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95130342022-09-28 Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis Yang, Xue-Gang Sun, Yan-Yuan Wang, Hai-Qing Li, De-Shan Xu, Guo-Hui Huang, Xiao-Qi Front Oncol Oncology PURPOSE: To compare the efficacy and safety of transarterial chemoembolization (TACE) plus sorafenib and immune checkpoint inhibitors (T+S+ICIs) and TACE plus sorafenib (T+S) when treating patients with advanced hepatocellular carcinoma (HCC) who have previously received locoregional treatment. MATERIALS AND METHODS: A retrospective analysis was performed on the patients with Barcelona Clinic Liver Cancer (BCLC) stage C HCC from May 2019 to December 2020. These patients were treated with locoregional therapy and showed radiographic progression after the treatment. Patients received either T+S+ICIs or T+S. The outcomes, including disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety, were compared. The propensity score matching (PSM) methodology was used to reduce the influence of confounding factors on the outcomes. RESULTS: Forty-three patients were included in the T+S group and 33 in the T+S+ICI group. After PSM (n = 29 in each group), patients who received T+S+ICIs had a higher DCR (82.8% vs. 58.6%, p = 0.043), longer median PFS (6.9 vs. 3.8 months, p = 0.003), and longer median OS (12.3 vs. 6.3 months, p = 0.008) than those who underwent T+S. Eastern Cooperative Oncology Group performance status was an independent predictor of PFS, and age was an independent predictor of OS. The incidence of treatment-related adverse events in T+S+ICIs was well controlled. CONCLUSIONS: Compared with TACE combined with sorafenib, TACE combined with sorafenib plus ICIs is a potentially safe and effective treatment regimen for patients with advanced HCC who previously received locoregional treatment. Frontiers Media S.A. 2022-09-13 /pmc/articles/PMC9513034/ /pubmed/36176392 http://dx.doi.org/10.3389/fonc.2022.914385 Text en Copyright © 2022 Yang, Sun, Wang, Li, Xu and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yang, Xue-Gang Sun, Yan-Yuan Wang, Hai-Qing Li, De-Shan Xu, Guo-Hui Huang, Xiao-Qi Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis |
title | Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis |
title_full | Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis |
title_fullStr | Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis |
title_full_unstemmed | Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis |
title_short | Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis |
title_sort | efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: a propensity score matching analysis |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513034/ https://www.ncbi.nlm.nih.gov/pubmed/36176392 http://dx.doi.org/10.3389/fonc.2022.914385 |
work_keys_str_mv | AT yangxuegang efficacyandsafetyoftransarterialchemoembolizationcombiningsorafenibwithorwithoutimmunecheckpointinhibitorsinpreviouslytreatedpatientswithadvancedhepatocellularcarcinomaapropensityscorematchinganalysis AT sunyanyuan efficacyandsafetyoftransarterialchemoembolizationcombiningsorafenibwithorwithoutimmunecheckpointinhibitorsinpreviouslytreatedpatientswithadvancedhepatocellularcarcinomaapropensityscorematchinganalysis AT wanghaiqing efficacyandsafetyoftransarterialchemoembolizationcombiningsorafenibwithorwithoutimmunecheckpointinhibitorsinpreviouslytreatedpatientswithadvancedhepatocellularcarcinomaapropensityscorematchinganalysis AT lideshan efficacyandsafetyoftransarterialchemoembolizationcombiningsorafenibwithorwithoutimmunecheckpointinhibitorsinpreviouslytreatedpatientswithadvancedhepatocellularcarcinomaapropensityscorematchinganalysis AT xuguohui efficacyandsafetyoftransarterialchemoembolizationcombiningsorafenibwithorwithoutimmunecheckpointinhibitorsinpreviouslytreatedpatientswithadvancedhepatocellularcarcinomaapropensityscorematchinganalysis AT huangxiaoqi efficacyandsafetyoftransarterialchemoembolizationcombiningsorafenibwithorwithoutimmunecheckpointinhibitorsinpreviouslytreatedpatientswithadvancedhepatocellularcarcinomaapropensityscorematchinganalysis |